期刊文献+

急性心肌梗死早期患者血清中可溶型ST2水平及其与心肌活性的关系 被引量:8

The levels of serum soluble ST2 in patients with early myocardial infarction and its relationship with myocardial viability
原文传递
导出
摘要 目的:探讨急性心肌梗死患者早期血清可溶性ST2(sST2)水平及其与心肌活性的关系。方法采用ELISA法检测30例发病12 h以内的非ST段抬高型心肌梗死(NSTEMI)患者血清sST2水平,于发病后第7天行心脏磁共振检查并根据磁共振结果将患者分为透壁增强组、非透壁增强组和混合组。于7-14 d行PCI术,并于术后6个月再次行心脏磁共振检查评估心肌活性,观察指标包括梗死心肌质量、左心室射血分数及室壁运动异常评分在术前及术后的变化及其与心肌梗死早期血清sST2水平的关系。结果透壁增强组血清sST2的水平较之非透壁增强组及混合组明显升高(P<0.05),混合组较非透壁增强组高(P<0.05);梗死心肌质量及室壁运动异常评分在3组患者PCI术后均减少,梗死心肌质量在非透壁增强组及混合组中减少有统计学差异(P<0.05),室壁运动异常评分在非透壁增强组降低显著(P<0.05);左心室射血分数在3组患者PCI术后均增加,在非透壁增强组及混合组中增加有统计学差异(P<0.05)。心肌梗死早期血清sST2水平与PCI术前及PCI术后6个月的心肌活性相关。结论急性心肌梗死早期血清中sST2的水平可反映心肌受损情况并可预测心肌梗死7 d PCI术前及PCI术后6个月的心肌活性。 ObjectiveTo investigate the levels of serum soluble ST2 in patients with early myocardial infarction and its relationship with myocardial viability.MethodsThe levels of serum soluble ST2 was measured with ELISA assay within 12 hours of the onset of NSTEMI in 30 patients, and 30 patients were subjected to cardiac magnetic resonance imaging on the 7th day of myocardial infarction and were divided into the following three groups by the transmural extent of myocardial infarction manifested in the delayed enhancement magnetic resonance imaging(DE-MRI):transmural enhancement group, non-transmural enhancement group and mixed group. All patients underwent PCI at 7-14 days after AMI and cardiac magnetic resonance imaging 6 months after the procedure to analyse the infarct mass, abnormal wall motion score and left ventricular ejection fraction(LVEF) and their relationship with the levels of serum ST2 in early stage of myocardial infarction.ResultsThe levels of serum ST2 in transmural enhancement group was significantly higher than that of non-transmural group and mixed group (P〈0.05), mixed groupvs. non-transmural (P〈0.05); Compared with the parameters before PCI, the infarct mass and abnormal wall motion score in three groups after PCI were decreased, but the infarct mass after PCI was significantly decreased in the non-transmural enhancement group and mixed group(P〈0.05). Abnormal wall motion score was significantly decreased in the non-transmural enhancement group after PCI(P〈0.05). LVEF was significantly improved after PCI in three groups, but the improvement in non-transmural enhancement group and mixed group were more significant(P〈0.05). The levels of serum soluble ST2 in patients with early myocardial infarction were related with myocardial viability before PCI and 6 months after the procedure.ConclusionThe levels of serum soluble ST2 might imply myocardial injury in early myocardial infarction, and could be used to predict myocardial viability on the 7th day of myocardial infarction before PCI and 6 months after the procedure.
出处 《中华临床医师杂志(电子版)》 CAS 2014年第13期13-16,共4页 Chinese Journal of Clinicians(Electronic Edition)
基金 山西省卫生厅科技攻关项目(20100205)
关键词 心肌梗死 可溶性ST2 心脏磁共振 心肌活性 SERUM ST2 Myocardial infarction Cardiac magnetic resonance imaging Myocardial viability
  • 相关文献

参考文献1

二级参考文献22

  • 1Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST- segment elevation myocardial infarction. J Am Coll Cardiol 2000; 36: 970-1062.
  • 2Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and Regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002; 106: 2961-2966.
  • 3Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, et al. Serum levels of the interleukin- 1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004; 109: 2186-2190.
  • 4Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial Infarction. Circulation 2008; 117: 1936-1944.
  • 5Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST elevation myocardial infarction: Comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J 2011; 61:1163-1170.
  • 6Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardio12010; 55: 243-250.
  • 7Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J 2010; 159: 788- 794.
  • 8Granger CB, Goldberg R J, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2006;163: 2345-2353.
  • 9Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1 like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479- 490.
  • 10Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, et al. Role of ST2 innon-st-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 2012; 58: 257-266.

共引文献26

同被引文献77

  • 1张云飞,吴先均,文秀华,易伟民,姜荣建.心肌肥厚机制研究进展[J].心血管病学进展,2005,26(2):197-200. 被引量:13
  • 2罗芳,周宪梁,惠汝太.神经内分泌细胞因子在心力衰竭中的作用机制及临床意义[J].中国分子心脏病学杂志,2007,7(2):108-111. 被引量:16
  • 3Task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patientspresenting with ST-segment elevation [ J ]. Eur Heart J, 2012, 33 (20) : 2569-2619. DOI: 10. 1093/eurheartj/ehs215.
  • 4Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes : executive summary- a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [ J ]. Circulation, 2014, 130 ( 25 ) : 2354-2394. DOI : 10.1161/cir. 0000000000000133.
  • 5Adams JE 3rd, Bodor GS, D6vila-Romen VG, et al. Cardiac troponin I. A marker with high specificity for cardiac injury [ J]. Circulation, 1993,88(1): 101-106.
  • 6Reiter M, Twerenbold R, Reichlin T, et al. Early diagnosis of acute myocardial infarction in patients with pre-existing coronary artery disease using more sensitive cardiac troponin assays [ J ]. Eur Heart J, 2012,33 ( 8 ) : 988-997. DOI: 10. 1093/eurheartj/ ehr376.
  • 7Lipinski M J, Baker NC, Escdrcega RO, et al. Comparison of conventional and high-sensitivity troponin in patients with chest pain: a collaborative meta-analysis [ J]. Am Heart J,2015,169 ( 1 ) :6-16. e6. DOI : 10. 1016/j. ahj. 2014.10. 007.
  • 8Lipinski M J, Baker NC, Escdrcega RO, et al. Comparison of conventional and high-sensitivity troponin in patients with chest pain: a collaborative meta-analysis [ J]. Am Heart J,2015,169 ( 1 ) :6-16. e6.DOI : 10. 1016/j. ahj. 2014.10. 007.
  • 9Wagner, GS, Roe CR, Limbird LE, et al. The importance of identification of the myocardial-specific isoenzyme of creatine phosphokinase (MB form ) in the diagnosis of acute myocardial infarction [ J ]. Circulation, 1973,47 (2) : 263-269.
  • 10Adams JE 3rd, Schechtman KB, Landt Y, et al. Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I [ J ]. Clin Cbem, 1994, 40 (7 Pt 1 ) :1291-1295.

引证文献8

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部